ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced plans for a Phase I adoptive cellular therapy clinical trial utilizing autologous T cells ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE